08:00 | Registration |
|
RNAi Screening |
| |
09:00 |  | Keynote Presentation Comparative Analysis of RNAi Screening Technologies at Genome-scale
Hakim Djaballah, CEO, Institute Pasteur - Korea, Korea South
We utilized the two most popular RNAi technologies (siRNA duplex and shRNA hairpin) in order to perform a head to head comparison of both performance and hit nomination output. Using a previously developed EGFP-based high content biosensor cell based assay, we first executed on an siRNA screen against the Ambion Silencer Select V4.0 library nominating 1,273 candidates, followed by a second shRNA screen against the TRC1 library nominating 497 candidates. I will present our findings and discuss some likely reasons for the observed differential outcomes.
|
|
10:00 | Coffee and Networking in Exhibition Hall |
10:45 | RNAi Screening Outcomes
Bhavneet Bhinder, Bioinformatics Engineer, Memorial Sloan Kettering Cancer Center, United States of America
We have performed several arrayed RNAi-based screens at our HTS Core Facility, using flavors from both siRNA and shRNA technologies. I will present and discuss the results providing specific example pertaining to gain of function assays and drug modifier screens.
|
11:30 | Pooled RNAi Screens in Xenograft Mouse Models
Donato Tedesco, Lead Research Scientist, Cellecta Inc, United States of America
We have adapted our pooled shRNA lentiviral libraries to track clonal cell populations derived from each transduction event in single-assay. This platform allows us to assess, in a single RNAi screen against many genetic targets, the phenotypic effect of each shRNA on multiple clonal populations. With this capability we have been able to perform reproducible RNAi "drop-out" screens in xenograft models where this sort of loss-of-function screen is typically confounded by massive proliferation of a small subset of sub-clones that produce the bulk of the tumor mass.
|
12:15 | Lunch & Networking in Exhibition Hall |
13:15 |  Free Workshop
Introduction of miRNA Research Reagents and Development of Novel Transfection Reagents using Combinatorial Chemistry and High-Throughput Cell Screening
|
13:30 | Poster Viewing Session |
|
RNAi Therapeutics |
| |
14:15 | Lethal Respiratory Viral Infections and the Delivery Barrier – Using Stealth siRNAs for Therapy
Nigel McMillan, Associate Professor, Griffith University, Australia
The main barrier to the clinical use of RNAi for respiratory viruses remains the lack of efficient delivery. Our stealth siRNA, delivery IV, bypasses the inflamed lung tissue and results in effective delivery, gene silencing and reduction in virus load. |
15:00 | Targeting Regulatory Antisense RNAs for Locus-Specific Gene Upregulation
Roya Pedram Fatemi, Staff Scientist, Faghihi Lab, University of Miami, United States of America
Targeting noncoding RNAs (ncRNAs) and ncRNA-binding domains of epigenetic enzymes offers a novel way of upregulating endogenous gene expression. We developed a pharmacological assay to quantify specific interactions between protein and ncRNAs that can serve to achieve locus-specific upregulation of selected genes.
|
15:45 | Coffee and Networking in Exhibition Hall |
|
Epigenetic Gene Silencing |
| |
16:30 | The Role of an HIV-encoded Antisense Long non-coding RNA in the Epigenetic Modulation of Viral Transcription
Sheena Saayman, Postdoctoral Fellow, The Scripps Research Institute, United States of America
My presentation will address the existence of an HIV-encoded antisense long non-coding RNA; its role in viral transcription regulation; and the epigenetic mechanism by which it functions.
|
17:15 | Epigenetics Market Analysis--From Research Trends to Clinical Trajectory
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
This presentation provides a snapshot of the Epigenetics marketplace from research trends, competitive landscape, and the penetrance of epigenetics towards the clinic as biomarkers and therapeutics. Data and analyses will be presented based on our continuing industry coverage of this space.
|
18:00 | Close of Day One |
